Buhler Returns to Rogan With 10x the Audience and Bigger News
When Brigham Buhler first appeared on JRE in early 2024, 73K people watched. This time, over 700K tuned in. The peptide conversation went mainstream in the gap between those two episodes, and the regulatory situation shifted underneath it.
This follow-up is not a rehash. The ground has moved. RFK Jr. entered the picture. The FDA began reconsidering its position on certain peptides. And the compounding pharmacy industry went from fighting for survival to potentially winning a major political battle. If the first episode was about the problem, this one is about what might come next.
RFK Jr. and the Peptide Policy Shift
The biggest development since Buhler's first appearance is the involvement of Robert F. Kennedy Jr. in health policy discussions that directly affect peptide access. Buhler discusses how RFK Jr.'s public statements about regulatory reform and pharmaceutical industry influence have created political momentum for expanded access to compounded peptides.
This is politically charged territory, and your opinion of RFK Jr. probably colors how you receive this information. But regardless of political alignment, the practical effect is real: there is now political pressure from visible public figures to re-examine the FDA's restrictions on compounded peptides. That pressure did not exist during Buhler's first appearance.
FDA Reclassification: What Actually Changed
Buhler gets into the specifics of FDA reclassification in more detail than the first episode. Some peptides that were previously removed from the compounding list are being reconsidered. The regulatory mechanism is complicated, involving Category 1, Category 2, and Category 3 designations that determine what compounding pharmacies can and cannot produce.
The short version: there is movement toward allowing compounding pharmacies to produce certain peptides again, but the process is slow and the outcome is not guaranteed. Buhler is cautiously optimistic but not declaring victory. He has seen regulatory winds shift before.
The Market Is Paying Attention
With 700K+ views on this episode alone, the market implications are obvious. Peptide therapy is not a fringe biohacker interest anymore. It is a multi-billion dollar market that pharmaceutical companies, compounding pharmacies, telehealth platforms, and wellness clinics are all competing to serve.
Buhler discusses what expanded access could mean economically. If compounding pharmacies can produce peptides like BPC-157 again at scale, prices drop. Access increases. The people who benefit most are patients who have been priced out of pharmaceutical alternatives or left without options when their compounding pharmacy stopped carrying certain products.
But expanded access also raises quality concerns. More demand means more suppliers, and not all of them will maintain high standards. Buhler acknowledges this and argues for smart regulation rather than blanket bans, meaning quality standards that protect consumers without eliminating access entirely.
What the Compounding Pharmacy Future Looks Like
The most forward-looking section of this conversation is about where the compounding pharmacy industry goes from here. Buhler sees a future where compounding pharmacies serve as a legitimate, regulated alternative to branded pharmaceuticals for certain categories of medications, including peptides.
This model already exists for other medications. Compounding pharmacies produce custom hormone replacement therapy, specialty topical medications, and pediatric formulations every day. The argument is that peptides should be treated the same way: available through compounding when a physician prescribes them, with appropriate quality oversight.
Whether that future materializes depends on politics, regulatory decisions, and market forces that are still in play. But the trajectory has shifted noticeably since Buhler's first Rogan appearance, and this episode captures that shift in real time.
RFK Jr. and the Specific Policy Shifts
The political angle in this episode is more concrete than you might expect. Buhler does more than say RFK Jr. supports peptide access and leave it there. He walks through specific actions and statements. RFK Jr. publicly questioned why the FDA was restricting compounds with decades of safety data while fast-tracking approvals for drugs with known side effect profiles. That framing resonated with a lot of people who felt the regulatory system was working against their interests.
Between the two Buhler episodes, real policy movement happened. The FDA opened a public comment period on the status of certain bulk drug substances used in compounding, which included several peptides. Industry groups and patient advocates flooded the comment period with submissions arguing for continued compounding access. Buhler describes this as a direct result of public pressure, some of which came from the visibility his first Rogan appearance created.
Whether RFK Jr.'s involvement will translate into lasting regulatory change is an open question. Political winds shift. But the fact that peptide access became part of a broader health freedom conversation in mainstream politics was new between these two episodes, and it changed the leverage that compounding pharmacy advocates had in regulatory discussions.
What Changed Between Episode One and Episode Two
The gap between Buhler's 2024 and 2025 Rogan appearances saw several concrete developments. The FDA issued additional warning letters to compounding pharmacies producing GLP-1 analogs, which generated backlash from patients who depended on compounded semaglutide. Multiple state pharmacy boards pushed back on federal overreach, arguing that compounding regulation should remain primarily a state-level function. And several pharmaceutical companies advanced branded versions of peptides that were previously available only through compounders, which Buhler sees as confirming his theory about the economic motivation behind restrictions.
The audience growth tells its own story. Going from 73K views to 700K means the peptide conversation reached a completely different scale of public awareness. Buhler notes that his inbox, his clinic's patient inquiries, and media interest all surged after the first episode. That visibility made it harder for the FDA to make quiet regulatory moves without public scrutiny.
What to Do With This Information Right Now
The political and regulatory content in this episode is interesting, but the practical question for most viewers is simpler: what does this mean for my access to peptides today? Based on what Buhler describes, here are the concrete takeaways.
If you are currently using compounded peptides through a physician, keep that relationship active. The providers who survived the 2024-2025 crackdown are generally the ones with strong legal compliance and quality standards. They are your best bet for continued access. If your current provider stopped carrying a peptide you use, ask them to refer you to another compounding pharmacy that found a compliant pathway. Physicians in this space talk to each other, and your doctor likely knows which pharmacies are still operating.
If you are new to peptides and this episode sparked your interest, start by finding a physician who specializes in peptide therapy. The Dr. Craig Koniver episode in the FormBlends library gives you a detailed picture of what a physician-supervised peptide program looks like, from initial bloodwork through ongoing monitoring. Do not skip the medical infrastructure and go straight to buying peptides online. The quality risks are real, and without baseline bloodwork, you have no way to track whether the peptides are actually doing anything.
If you are interested in the political side and want to support expanded access, Buhler mentions several advocacy organizations that accept public comments on FDA rulemaking. The public comment periods he references are real mechanisms for influencing policy. They are not petition drives that go nowhere. Federal agencies are required to read and respond to public comments during rulemaking, and the volume of comments on peptide-related proposals has been historically high.
How the Three Buhler Episodes Build on Each Other
If you are watching this episode in isolation, you are getting chapter two of a three-part story. The first Buhler JRE appearance (episode 2079, also covered on FormBlends) lays the groundwork: what peptides are, how compounding pharmacies work, and why the FDA started restricting access. That episode is the "here is the problem" chapter. This second appearance is the "here is what might change" chapter, with the RFK Jr. involvement and the FDA reconsideration adding political momentum.
The third episode (JRE 2469, March 2026) is the most current and practical. It covers what you can actually get as of early 2026, how to vet providers, and specific quality control red flags. If you can only watch one, the third episode is the most immediately useful. But watching all three gives you the full arc: how we got here, what changed, and where things stand now.
The evolution of the audience across these three episodes also tells a story. From 73K to 700K to 364K (and growing). Peptide access went from a niche concern to a mainstream health policy issue in less than two years, and these three conversations are a primary reason why.
The Compounded GLP-1 Angle Most People Missed
Buried in the middle of this episode is a discussion that got less attention than the BPC-157 regulatory fight but may affect more people. Compounding pharmacies had been producing semaglutide and tirzepatide at significantly lower cost than brand-name Ozempic and Mounjaro. When the FDA cracked down on compounders, millions of patients who relied on these affordable versions were at risk of losing access.
Buhler frames this as the same dynamic playing out with GLP-1 drugs that happened earlier with peptides. Brand-name manufacturers have a financial interest in eliminating cheaper compounded alternatives. The shortage designations that allowed compounding were always temporary, and as branded supply caught up, the regulatory window for compounders started closing.
For patients on compounded semaglutide, this is not abstract policy. It is the difference between a $200 monthly medication and a $1,300 one. Buhler argues that the health outcomes for these patients should matter more than brand-name manufacturer profits, and the public response to this part of the conversation was intense. The compounded GLP-1 access issue became one of the most discussed health policy topics in 2025, and it fed directly into the broader "health freedom" framing that Buhler and others have used to build political support for compounding access.
The Bigger Picture for Consumers
If you watched the first Buhler episode and came away frustrated, this one offers reasons for cautious optimism. The conversation around peptide access is no longer happening in obscure regulatory hearings. It is on the biggest podcast in the world. Public figures are weighing in. The pharmaceutical industry's ability to quietly restrict access through regulatory channels is being challenged openly.
None of that means peptides are going to be available at your corner pharmacy tomorrow. Regulatory change is slow. But the direction of travel appears to be toward more access, not less. And if you are someone who has used peptides and wants to continue, or someone who has been curious but put off by the regulatory uncertainty, that matters.